secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274192
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q3 2025: Net loss $13.1M, China sale ~$220M, cash $121.1M into 2028
----------------------------------------------------------------------------

- Net loss from continuing ops $13.1M ($3.25 loss per share) vs $48.3M ($12.01 loss) YoY.
- Total revenue from continuing ops $1.1M, up from $0.1M YoY.
- Completed sale of FibroGen China to AstraZeneca for ~$220M ($85M enterprise + $135M net cash).
- Cash, equivalents, receivables, and investments $121.1M; cash runway into 2028; repaid Morgan Stanley term loan.
- Initiated Phase 2 trial of FG-3246 in mCRPC; FDA agreed on Phase 3 roxadustat design for LR-MDS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/0001193125-25-274192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer